{"title":"彻底预防糖尿病肾病可行吗?","authors":"U. A. Sharaf El Din, M. Salem","doi":"10.47363/jone/2022(2)124","DOIUrl":null,"url":null,"abstract":"When SGLT2Is were first introduced as hypoglycemic agents during the year 2008, no body was aware about their protective action on the heart, kidney, and retina of patients suffering type 2 diabetes mellitus (T2DM). SGLT2Is have revolutionized the treatment of T2DM patients with established or at risk for diabetic kidney disease (DKD). When Dapagliflosin was studied in T2DM patients with estimated glomerular filtration rate [eGFR] >90 mL/min/1.73m2, and normal urine albumin excretion, these cases were still susceptible to develop the renal end points. These results have raised the question about the ideal time to use SGLT2Is to completely abort the incidence of DKD. This review will try to answer this question.","PeriodicalId":145640,"journal":{"name":"Journal of Nephrology & Endocrinology Research","volume":"9 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Is it Feasible to Completely Prevent Diabetic Kidney Disease?\",\"authors\":\"U. A. Sharaf El Din, M. Salem\",\"doi\":\"10.47363/jone/2022(2)124\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"When SGLT2Is were first introduced as hypoglycemic agents during the year 2008, no body was aware about their protective action on the heart, kidney, and retina of patients suffering type 2 diabetes mellitus (T2DM). SGLT2Is have revolutionized the treatment of T2DM patients with established or at risk for diabetic kidney disease (DKD). When Dapagliflosin was studied in T2DM patients with estimated glomerular filtration rate [eGFR] >90 mL/min/1.73m2, and normal urine albumin excretion, these cases were still susceptible to develop the renal end points. These results have raised the question about the ideal time to use SGLT2Is to completely abort the incidence of DKD. This review will try to answer this question.\",\"PeriodicalId\":145640,\"journal\":{\"name\":\"Journal of Nephrology & Endocrinology Research\",\"volume\":\"9 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Nephrology & Endocrinology Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.47363/jone/2022(2)124\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nephrology & Endocrinology Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47363/jone/2022(2)124","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Is it Feasible to Completely Prevent Diabetic Kidney Disease?
When SGLT2Is were first introduced as hypoglycemic agents during the year 2008, no body was aware about their protective action on the heart, kidney, and retina of patients suffering type 2 diabetes mellitus (T2DM). SGLT2Is have revolutionized the treatment of T2DM patients with established or at risk for diabetic kidney disease (DKD). When Dapagliflosin was studied in T2DM patients with estimated glomerular filtration rate [eGFR] >90 mL/min/1.73m2, and normal urine albumin excretion, these cases were still susceptible to develop the renal end points. These results have raised the question about the ideal time to use SGLT2Is to completely abort the incidence of DKD. This review will try to answer this question.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
